Internalization and recycling of ALCAM/CD166 detected by a fully human single-chain recombinant antibody

Tiziana Piazza1, Emanuela Cha, Italia Bongarzone

  • 1Istituto Nazionale per la Ricerca sul Cancro, Largo R. Benzi 10, 16132 Genova, Italy.

Insights

Researchers developed a novel single-chain antibody fragment (scFv) targeting Activated Leukocyte Cell Adhesion Molecule (ALCAM/CD166). This scFv facilitates targeted delivery of immunotoxins into tumor cells, demonstrating its potential for cancer therapy.

Area of Science:

  • Immunology
  • Molecular Biology
  • Oncology

Background:

  • Activated Leukocyte Cell Adhesion Molecule (ALCAM/CD166) is an immunoglobulin superfamily member involved in cell-cell interactions.
  • ALCAM/CD166 plays a role in various biological processes, including immune responses and cancer progression.

Purpose of the Study:

  • To develop and characterize a fully human single-chain antibody fragment (scFv) targeting ALCAM/CD166.
  • To investigate the potential of this scFv for targeted cancer therapy through immunotoxin delivery.

Main Methods:

  • Phage display library selection and cell panning to isolate the I/F8 scFv.
  • Mass spectrometry (MALDI-TOF) for protein identification.
  • Binding assays, internalization studies, and immunofluorescence microscopy.

Main Results:

  • The I/F8 scFv specifically binds to ALCAM/CD166 across human, monkey, and murine species.
  • I/F8 scFv binding induces ALCAM/CD166 internalization via a clathrin-dependent pathway.
  • ALCAM/CD166-I/F8 complexes are recycled to the cell surface.
  • I/F8 scFv-saporin immunoconjugates selectively kill ALCAM/CD166-expressing tumor cells.

Conclusions:

  • The I/F8 scFv is a promising tool for functional studies of ALCAM/CD166.
  • The I/F8 scFv enables efficient intracellular delivery of effector moieties for targeted cancer therapy.

Related Concept Videos